Home » Topics » Regulatory » EMA

EMA
RSS

EMA considers postapproval commitment fulfilled for Ceplene/IL-2 in AML

June 2, 2010

Wyeth Europa notifies EMA of withdrawal of MAA for Brilence

June 1, 2010

FDA and EMA approve reanalysis of images from phase III RG-1068 trial

May 31, 2010

Prolia obtains marketing authorization in E.U.

May 31, 2010

Vaxon's Vx-001 to advance from phase I/II to phase III in NSCLC

May 21, 2010

EMA issues positive opinion for orphan status of AEZS-108 in ovarian cancer

May 19, 2010

CHMP adopts positive opinion for variation to terms of Reyataz marketing authorization

April 28, 2010

CHMP recommends conditional marketing approval for Votrient

April 27, 2010

CHMP recommends Seroquel XR as add-on treatment for major depressive disorder

April 27, 2010

EMA's CHMP recommends extending indication of tocilizumab

April 27, 2010

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...